glp 1 vs glp 1 agonist GLP-1 Receptor Agonists as Treatments for Type 2 Diabetes GLP-1 receptor agonists show promise
Description
Efficacy The DURATION-1 study compared exenatide once weekly with exenatide twice daily in patients with uncontrolled T2D being treated with either diet, one or two oral therapies [Drucker et al
This case highlights the serious and sometimes life-threatening risks posed by unapproved, unregulated medications
Cost Considerations Novo Nordisk has indicated a starting list price near ~$149/month for the oral starting dose, considerably lower than many injectable equivalents
The rapid rise of GLP-1 expenses led state officials to announce in December that Medicaid would stop paying for the drugs when they are prescribed for obesity alone
doi: 10.1074/jbc.270.21.12646
